Table 2.
Structural and activity parameters of the undecapeptides generated in this study
| Peptides | <H>a | <μH> b | MHCc (μg/ml) | TI′ (MHC/GM)d | ||
|---|---|---|---|---|---|---|
| (+)e | (-)f | (+ , -) g | ||||
| Omiganan | -0.31 | 0.28 | 100 | 13.4 | 1.5 | 4.0 |
| GA-W2 (#0.0) | 0.08 | 0.30 | 25 | 1.0 | 0.3 | 0.5 |
| GA-W3 (#1.0) | 0.14 | 0.28 | 50 | 9.5 | ≤ 1.1 | ≤ 2.9 |
| GA-W4 (#1.1) | 0.16 | 0.27 | 25 | 6.8 | ≤ 0.1 | ≤ 0.6 |
| GA-K3 (#2.0) | 0.01 | 0.34 | 50 | 8.0 | 2.3 | 4.0 |
| GA-K4 (#2.1) | -0.10 | 0.44 | 6.3 | 1.4 | 0.3 | 0.6 |
| GA-K4L (#2.11) | -0.07 | 0.47 | 12.5 | 1.7 | 0.3 | 0.6 |
| GA-K4A (#2.12) | -0.15 | 0.41 | ≥ 200 | ≥ 4.0 | ≥ 1.5 | ≥ 2.3 |
| GA-K4AL (#2.13) | -0.12 | 0.43 | ≥ 200 | ≥ 31.7 | ≥ 16.0 | ≥ 21.7 |
amean residue hydrophobicity
bmean residue hydrophobic moment
cminimal hemolytic concentration
dpseudo-therapeutic index
eagainst 4 Gram-positive strains tested
fagainst 5 Gram-negative strains tested
gagainst all of the 9 strains tested